Nucala 100 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FQWE6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,318
Award facts
- Contract value 100% obligated
- $19,318.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $19,318.30 to DMS Pharmaceutical Group Inc. for NUCALA 100 mg/mL syringes, with an ultimate completion date of December 4, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without set-aside designation, demonstrating the company's competitive capability in unrestricted federal procurement. The delivery order was issued under the company's existing Indefinite Delivery Contract established through the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs for Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group Inc. holds a single-award IDC under PPV-G GEN V designated as contract SPE2DR, awarded on November 13, 2025, with a ceiling value of $499,999,999 and an ultimate completion date of December 31, 2036. The contract is structured as a 30-month base period with three 30-month option periods, positioning the company as one of multiple regional prime vendor contractors. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group distributes a comprehensive range of pharmaceuticals including branded and generic prescription medications, biologics, specialty pharmaceuticals, and medical consumables to support Department of Defense military healthcare operations globally. The company has demonstrated substantial federal contracting activity through numerous delivery orders issued by DLA's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FQWE6?
SPE2DR26FQWE6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FQWE6 worth?
The government has obligated $19,318 on SPE2DR26FQWE6.
Is contract SPE2DR26FQWE6 an order under another contract?
Yes. SPE2DR26FQWE6 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWE6 competed?
The extent of competition for SPE2DR26FQWE6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award